Next Article in Journal
Association between Exposure to Influenza Vaccination and COVID-19 Diagnosis and Outcomes
Previous Article in Journal
SARS-CoV-2 Proteins Induce IFNG in Th1 Lymphocytes Generated from CD4+ Cells from Healthy, Unexposed Polish Donors
Article

The Impact of Serotype Cross-Protection on Vaccine Trials: DENVax as a Case Study

by 1,2,3,*,† and 1,2,†
1
Dipartimento di Matematica, Università degli Studi di Trento, 38100 Trento, Italy
2
Basque Center for Applied Mathematics (BCAM), E-48009 Bilbao, Basque Country, Spain
3
Ikerbasque, Basque Foundation for Science, E-48009 Bilbao, Basque Country, Spain
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Vaccines 2020, 8(4), 674; https://doi.org/10.3390/vaccines8040674
Received: 26 September 2020 / Revised: 4 November 2020 / Accepted: 7 November 2020 / Published: 12 November 2020
(This article belongs to the Section Epidemiology)
There is a growing public health need for effective preventive interventions against dengue, and a safe, effective and affordable dengue vaccine against the four serotypes would be a significant achievement for disease prevention and control. Two tetravalent dengue vaccines, Dengvaxia (CYD-TDV—Sanofi Pasteur) and DENVax (TAK 003—Takeda Pharmaceutical Company), have now completed phase 3 clinical trials. Although Dengvaxia resulted in serious adverse events and had to be restricted to individuals with prior dengue infections, DENVax has shown, at first glance, some encouraging results. Using the available data for the TAK 003 trial, we estimate, via the Bayesian approach, vaccine efficacy (VE) of the post-vaccination surveillance periods of 12 and 18 months. Although better measurement over a long time was expected for the second part of the post-vaccination surveillance, variation in serotype-specific efficacy needs careful consideration. Besides observing that individual serostatus prior to vaccination is determinant of DENVax vaccine efficacy, such as for Dengvaxia, we also noted, after comparing the VE estimations for 12- and 18-month periods, that vaccine efficacy is decreasing over time. The comparison of efficacies over time is informative and very important, and brings up the discussion of the role of temporary cross-immunity in dengue vaccine trials and the impact of serostatus prior to vaccination in the context of dengue fever epidemiology. View Full-Text
Keywords: dengue; dengue vaccine trials; vaccine efficacy; cross-protection; serotypes; serostatus; Bayesian approach dengue; dengue vaccine trials; vaccine efficacy; cross-protection; serotypes; serostatus; Bayesian approach
Show Figures

Figure 1

MDPI and ACS Style

Aguiar, M.; Stollenwerk, N. The Impact of Serotype Cross-Protection on Vaccine Trials: DENVax as a Case Study. Vaccines 2020, 8, 674. https://doi.org/10.3390/vaccines8040674

AMA Style

Aguiar M, Stollenwerk N. The Impact of Serotype Cross-Protection on Vaccine Trials: DENVax as a Case Study. Vaccines. 2020; 8(4):674. https://doi.org/10.3390/vaccines8040674

Chicago/Turabian Style

Aguiar, Maíra, and Nico Stollenwerk. 2020. "The Impact of Serotype Cross-Protection on Vaccine Trials: DENVax as a Case Study" Vaccines 8, no. 4: 674. https://doi.org/10.3390/vaccines8040674

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop